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Abstract
Background: Reporting of the clinical significance of observed changes is recommended when publishing mental
health treatment outcome studies and is increasingly used in routine outcomes monitoring systems. Since recovery
rates vary with the method chosen, we investigated the validity of classifications of clinically significant change
when the Jacobson-Truax method and the Hageman-Arrindell method were used.
Methods: Of 718 inpatients who completed the Depression Anxiety Stress Scales (DASS-21) and Quality of Life
Enjoyment and Satisfaction Questionnaire at admission and discharge to a psychiatric clinic, 355 were invited (and
119 agreed) to complete the questionnaires and the Recovery Assessment Scale six weeks post discharge.
Results: Both the JT and HA methods showed comparably good validity when referenced against the other
indices. Clinically significant change on the DASS-21 was related to a greater consumer-based sense of recovery,
greater perceived quality of life, and fewer readmissions to hospital within 28 days of discharge.
Conclusions: Since there was found to be no advantage to using one method over another when recovery is of
interest, the simpler JT method is recommended for routine usage.
Keywords: Clinical significance, Validity, Outcomes, Recovery, Quality of life
Background
Clinical significance categorisations aim to provide a
meaningful classification of treatment outcomes [1, 2].
The most widely used calculation for clinical significance
is the Jacobson-Truax method [3, 4] which considers the
reliability of the change made (Reliable Change Index;
RCI) in the context of the overall distribution that the
patient is likely to belong to post-treatment (functional
or dysfunctional). Clients moving reliably into the func-
tional distribution are recovered. Clients have improved
if they have made a reliable change but remain in the
dysfunctional population, unchanged if they have not made
a reliable change, and deteriorated if they have reliably
worsened.
Given recommendations to report rates of clinically
significant change, it is important that classifications
are valid [5]. Supporting the ecological validity of the
Jacobson-Truax (JT) method, clinically significant change
on the Symptom Check List-90 Revised (SCL-90R) [6]
relates to client’s satisfaction with therapy [7] and client
and therapist-rated change [8]. The convergent validity
of classifications of clinically significant change for de-
pressed patients across different depression measures
has also been demonstrated [9]. Likewise, clients who
made a clinically significant change on the Outcomes
Questionnaire-45 (OQ-45) [10] also made clinically sig-
nificant change on the SCL-90R, the Social Adjustment
Rating Scale, the Inventory of Interpersonal Problems, and
the Quality of Life Inventory [11]. Newnham, Harwood,
and Page [12] determined that clinically significant change
on the Medical Outcomes Short Form Questionnaire
(SF-36) [13] was associated with a greater perceived
quality of life, as well as greater clinician-rated function-
ing. Furthermore, Wise [14] demonstrated that 56 % of
substance abuse clients who made a reliable change on
the SCL-90R had a clinically meaningful change in the
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percentage of days abstinent from substances. Ronk and
colleagues [15] demonstrated that when clinical signifi-
cance based on the JT method is assessed using different
measures related to depression (Quality of Life Enjoyment
Scale; Depression scale of the DASS-21; and SF-36 Mental
Health Scale), the results are largely convergent. There-
fore, these findings support the ecological validity of
clinical significance classifications for the JT method of
calculating the clinical significance.
Potential alternatives to JT method
However, there exist several other methods to classify
the clinical significance of a treatment outcome, includ-
ing the Gulliksen Lord Novick method (GLN) [16, 17],
the Nunnally-Kotsch method (NK) [18], the Edwards-
Nunnally method (EN) [19], the Hageman-Arrindell
method (HA) [20] and Hierarchical Linear Modelling
(HLM) [21]. McGlinchey, Atkins, and Jacobson [22]
found that the HA method classified clients significantly
differently to the JT, GLN, and EN methods. The HA
method was less sensitive since a greater amount of client
change was required for a client to be considered reliably
improved. Similarly, Ronk, Hooke, and Page [15] found that
while the JT, GLN, NK, EN calculation methods yielded
similar rates of clinically significant change, the HA method
produced consistently distinct classifications. Therefore, the
HA method is more conservative in assigning classifications
of recovered to patients than other methods.
The reason for differences between the classification
rates lies in the method of calculations. The JT method
classifies a client’s outcome based on the reliability of
the pre- to post-treatment change and whether or not
the client has moved from the dysfunctional population
to the functional population. The calculation uses cli-
ents’ observed scores, which contain measurement error.
The HA method attempts to correct regression to the
mean by using an approximation of true scores rather
than observed scores. In addition, while the JT method
uses a cut-off score to separate the functional and dys-
functional distributions, the HA method uses a cut-off
index score which allows users to determine that a client
has passed the cut-off score in the correct direction with
95 % confidence.
These differences between rates of recovery based on
the JT and HA methods of classifying change need to be
explored. However, as previously stated by Hsu [23], one
method cannot be recommended over another based
purely on higher or lower rates of classifications of clinically
significant change. It is important to determine whether
one method’s recovered clients experience changes in other
areas of importance, such as quality of life, that reasonably
correspond with the concept of recovery, when compared
to other classification methods (see [22]). Thus, analyses
will only be conducted using the JT and HA methods, since
the remaining three methods explored in McGlinchey
et al., [22] and Ronk et al. [15] were largely similar to
the JT method.
Recovery evaluation
While in clinical research symptom reduction is often
synonymous with recovery, ‘consumer-based recovery’
captures the notion that there are many facets to recov-
ery, including hope, healing, empowerment, self-identity,
pursuing meaningful goals, developing connections with
others, and having a sense of control [24, 25]. This def-
inition of recovery posits that a focus on symptom re-
duction alone is too narrow, as clients who report severe
symptoms can still experience improvements in other
aspects of their lives [26, 27] and vice versa. Therefore,
in the present study the first recovery evaluation variable
is a consumer-based measure of recovery; the Recovery
Assessment Scale (RAS) [28].
Another domain associated with the consumer-based
conceptualisation of recovery is quality of life [29]. Al-
though symptoms and quality of life are not mirror images
on one another, an increase in symptoms relates to a de-
crease in quality of life for patients with Major Depressive
Disorder [30]. If the inverse of this is also true, and clinic-
ally significant change on a symptom measure relates to
significant improvements in perceived quality of life, then
this will provide convergent validity for classifications of
the recovered category. Therefore, the second recovery
evaluation measure chosen is the Quality of Life Enjoy-
ment and Satisfaction Questionnaire (Q-LES-Q) [31, 32].
In addition, it is important to include an objective in-
dicator of treatment outcome. Whether or not a patient
has been readmitted to an inpatient facility soon after
their discharge has a logical relationship to outcome.
Readmission to hospital, specifically within the 28 day
period following discharge, is used as a national clinical
indicator of the quality of care [33]. Readmission to
hospital within 28 days is considered a poor outcome
associated with more severe symptoms [34, 35], and prior
hospital admissions [36]. Specifically, being readmitted to
hospital within 28 days is not consistent with that person
being considered as recovered [37, 38].
Current study
The focus of the current study is on the categorisation
of patients as recovered, which is defined according to
statistical methods for reporting clinical significance as
both (a) making a statistically reliable change during
treatment; and (b) belonging to the ‘functional’ population
at post-treatment. Firstly, we aim to examine the validity
of the JT method for assessing clinically significant change
by exploring the relationship between classifications of
recovered and three variables related to the concept of re-
covery. It is necessary to explore the links between clinical
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significance classifications and these criterion measures
before any further assumptions can be made about the
validity of the clinical significance methodology. It is
hypothesised that those patients who are classified as re-
covered by either the JT or HA methods, when compared
to those who are not classified as recovered, will:
(a)score higher on the Recovery Assessment Scale
(RAS) [39, 40] indicative of a greater sense of
consumer-based recovery;
(b)score higher on the Quality of Life Enjoyment and
Satisfaction Questionnaire (Q-LES-Q) [31],
indicative of a greater perceived enjoyment and
satisfaction with life; and
(c)have lower rates of readmission to hospital within
28 days of their discharge, indicative of a more
successful post-discharge period.
Secondly, if there is an association between a clinically
significant change and our three criterion measures, we
aim to determine whether one method demonstrates more
convergent validity than another.
Method
Participants and procedure
Participants were 718 consecutively admitted patients
with complete data discharged from a private psychiatric
hospital between April 2011 and January 2012. The mean
age was 42.9 years (SD = 15.1) and the mean length of hos-
pital stay was 17.4 days (SD = 14.8). Married patients made
up 50.3 % of the sample, 33.2 % were single, and 16.5 %
were separated, divorced, or widowed. Participants were
given diagnoses by their treating psychiatrist. The sample
consisted of patients with primary diagnoses of mood
(56.1 %), anxiety (19.4 %), substance use (13.7 %), and
psychotic disorders (5.9 %) as well as other diagnoses
(4.9 %).
While in hospital, patients complete a range of group
therapies led by clinical psychologists and occupational
therapists including cognitive behavioural therapy, inter-
personal therapy, and structured activity-based therapy
while under the care of nursing staff and their psych-
iatrist. As part of routine quality assurance at the hos-
pital, patients were invited to complete questionnaire
measures at both admission and discharge. Participants
provided informed consent and the study had ethical
approval (#2557).
Patients completed the DASS-21 and Q-LES-Q at ad-
mission and discharge. A total of 718 patients discharged
during the period from April 2011 and January 2012
completed both measures at admission and at discharge.
These data were used to assess clinical significance of
change from pre- to post-treatment as measured by the
DASS-21 as well as quality of life score at discharge and
readmission to hospital within 28 days of discharge. A
cohort of 355 patients discharged during the first half of
the study period was invited to complete the DASS-21
and RAS six weeks after discharge. The total response
rate was 41.1 %, which compares favourably with other
mail-out surveys. Only cases with complete data (n = 119)
were used in the analyses of scores six weeks post-
discharge. Age differed significantly between responders
(M = 48.0 years; SD = 15.7) and non-responders (M =
40.4 years; SD = 15.0); t(353) = 4.68, p < .05. Length of stay
in hospital was longer (M = 19.2 days; SD = 15.8) for pa-
tients who responded compared to patients who did not
respond (M = 16.1 days; SD = 12.2); t(353) = 2.16, p < .05.
There were no significant differences between responders
and non-responders in symptom severity at admission or
discharge and prior admissions to hospital.
Measures
Recovery Assessment Scale (RAS)
Scores on the RAS have high internal consistency (α = .93)
and test-retest reliability (α = .88) [28, 41]. The validity of
RAS score interpretations demonstrates convergent valid-
ity [28, 42] with correlations with other recovery-oriented
scales ranging from r = .20 - .68. The RAS demonstrates
divergent validity from symptom or function-based mea-
sures such as the Health of the Nation Outcome Scales
(HoNOS) [43, 44]. The RAS originally had 41 items, how-
ever Hancock et al. [40] removed 10 items due to poor fit
statistics or item redundancy, resulting in a 31-item scale
that map more closely to processes associated with con-
sumer based recovery in the literature (e.g., symptom
management, a sense of control). Based on results of the
Rasch analysis [40], the 31-item version of the RAS with a
five-point rating scale (1 = strongly disagree; 5 = strongly
agree) was chosen to determine recovery scores in the
current study. Scores are summed to form one score
representing ‘recovery’, with a minimum possible score of
31 and a maximum possible score of 155. A higher score
indicates a stronger experience of recovery.
Depression Anxiety Stress Scales 21 (DASS-21)
Lovibond and Lovibond [45] the DASS-21 measures
levels of depression, anxiety, and stress. Respondents
rate 21 items such as “I felt down-hearted and blue” and
“I felt that life was meaningless” on a scale ranging from
zero to three. Within each scale, the total score is doubled
so that the minimum score is zero and the maximum
score is 42. The scores on each scale have high internal
consistency (α = .88 for Depression; α = .82 for Anxiety
and α = .90 for Stress; [46]) and the interpretations of the
construct demonstrate good convergent and discriminant
validity [45–48].
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Quality of Life Enjoyment and Satisfaction Questionnaire-
Short Form (Q-LES-Q)
Endicott et al. [31] the Q-LES-Q is a 14 item self-report
scale assessing quality of life across domains such as
physical health, and household activities. Respondents
rate their satisfaction with each domain on a 5-point scale.
Item scores are added and transformed onto a scale ran-
ging from 0 to 100, with higher scores indicative of higher
perceived quality of life. Scores on the Q-LES-Q demon-
strate high internal consistency (>.90) and test-retest reli-
ability (.63–.89), and the interpretations of the scores
show good construct validity [30, 32, 49].
Clinical significance calculation methods
The current study used the Jacobson-Truax method of
clinical significance classification [3, 4] and the Hageman
Arrindell method of clinical significance classification
[19]. When using the JT the cut-off between the dys-
functional population and the functional population can
be calculated using one of three formulas. The present
study used cut-off ‘C’ to represent the cut-off between
the functional and dysfunctional population as recom-
mended by Hsu [50]. In addition to classifications of
clinical significance made using scores from the time of
pre-treatment to post-treatment, classifications were also
calculated using pre-treatment scores and scores at six
weeks post-treatment.
Data analysis
Independent sample t-tests and corresponding measure
of effect size, Cohen’s d, will be used to evaluate the dif-
ference in RAS scores and quality of life scores for those
patients who make a clinically significant change on the
DASS-21 and those who do not. Chi-squared analysis
(χ2) and corresponding measure of effect size, phi (ɸ)
will be used to assess the difference in readmission rates
within 28 days between those patients who make a clin-
ically significant change on the DASS-21 and those who
do not. Following Cohen [51], the conventions for small,
medium and large effect sizes are respectively .20, .50
and .80 for Cohen’s d, and .10, .30 and .50 for Φ (and
the Pearson correlation coefficient, r).
Results
Scores for each scale of the DASS-21 decreased between
pre-treatment and post-treatment, and quality of life in-
creased (Table 1). DASS-21 scales at pre-treatment,
post-treatment, and between change scores were moder-
ately inter-correlated. Pre-treatment correlations were
significant (p < .01); r(Dep & Anx) = .52, r(Dep & Str) = .57,
and r(Anx & Str) = .69. Post-treatment correlations were
significant (p < .01); r(Dep & Anx) = .70, r(Dep & Str) = .78,
and r(Anx & Str) = .74. Correlations between change
scores were also significant (p < .01); r(Dep & Anx) = .59,
r(Dep & Str) = .68, and r(Anx & Str) = .69.
When patients are classified using the JT method,
there are higher rates of clinically significant change than
when the HA method is used (Table 2). This suggests that
the HA method is more stringent in its classification of
recovery. Classifications of deterioration yield identical
proportions with both methods. Of the 718 patients
discharged, 64 (8.9 %) were readmitted within 28 days
of their discharge from hospital.
Recovery assessment scale
Of 119 patients who completed the RAS six weeks follow-
ing discharge from hospital (Table 3), between 18.5 and
56.3 % of patients were classified as recovered, depending
on which DASS-21 scale a patient was measured on and
with which clinical significance calculation method. Pa-
tients who were classified as recovered on each scale of the
DASS-21 according to both the JT and HA methods scored
significantly higher on the RAS than those who made no
clinically significant change. A similar pattern was found
when patients who were classified as recovered according
to the HA method were compared with those who were
not. This suggests that both the JT and HA methods for
evaluating clinically significant change (i.e., a classification
of recovered) demonstrate construct validity, as clinically
significant change on a symptom measure, the DASS-21, is
related to higher scores on the RAS, representative of a
more positive perception of ‘consumer-based’ recovery.
Table 1 Means and standard deviations (in parentheses) for the DASS-21, Q-LES-Q and RAS at pre-treatment, post-treatment, and six
weeks post-treatment
DASS-21 scale Q-LES-Q RAS
n Depression Anxiety Stress
Pre-treatment 718 28.27 (11.84) 20.53 (10.85) 26.96 (10.24) 32.59 (17.42) -
Post-treatment 718 12.82 (10.79) 10.18 (8.95) 13.63 (9.69) 52.97 (18.69) -
Six weeks post-treatment 119 12.66 (11.69) 9.78 (9.16) 14.13 (10.53) - 119.15 (18.26)
Range of measure 0 – 42a 0 – 42a 0 – 42a 0 – 100b 31 – 155b
DASS-21 depression anxiety stress scales – 21, Q-LES-Q quality of life enjoyment and satisfaction questionnaire, RAS recovery assessment scale
ahigher scores reflect more negative functioning. bhigher scores reflect more positive functioning
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Quality of life
Of 718 patients who completed the Q-LES-Q at post-
treatment (Table 4), between 19.1 and 58.9 % were clas-
sified as having achieved a clinically significant change,
depending on which DASS-21 scale they were assessed
on and clinical significance classification method. Per-
ceived quality of life was greater for patients classified as
recovered by the JT and HA methods than those who
were not. These findings support the construct validity
of clinically significant change as calculated by both the
methods.
Readmission to hospital within 28 days of discharge
A significantly higher proportion of patients who were not
considered recovered at discharge were readmitted within
28 days than those who were considered recovered by the
JT method with the Depression scale (χ2(1) = 9.80, p = .002,
ɸ = .117; Fig. 1), the HA method with the Depression scale
(χ2(1) = 6.93, p = .008, ɸ = .098), and the HA method with
the Stress scale (χ2(1) = 4.259, p = .039, ɸ = .077). The
remaining classification methods yielded no significant dif-
ferences between readmission rates for recovered compared
to non-recovered patients. Since patients who were not
considered to have made a clinically significant change on
the Depression scale were approximately twice as likely to
be readmitted within 28 days of discharge than those pa-
tients whose change had been considered clinically signifi-
cant, this provides support for the construct validity of
recovery as evaluated by both calculation methods but only
when classifications are based on certain DASS-21 scores.
Discussion
When patients who received a classification of recovered
at post-treatment (calculated using the JT method with
DASS-21 scores) were compared to those who were not
considered recovered, the recovered patients had signifi-
cantly higher RAS scores, indicative of a more positive
consumer-based sense of recovery, and significantly higher
Q-LES-Q scores, indicative of a greater perception of life
enjoyment and satisfaction. The rate of hospital readmis-
sion within 28 days of discharge was significantly lower for
those considered recovered according to the JT method
with the Depression scale, and the HA method with the
Depression and Stress scales. These findings provide
Table 2 Percentage of patients classified into each clinical significance category by the Jacobson-Truax (JT) method and the
Hageman-Arrindell (HA) method based on DASS-21 scale scores calculated across two time periods
DASS-21 Depression scale DASS-21 Anxiety scale DASS-21 Stress scale
JT method HA method JT method HA method JT method HA method
Pre-treatment to post-treatment (n = 718)
Recovered 57.5 % 42.1 % 36.8 % 19.1 % 58.9 % 46.7 %
Improved 14.9 % 35.9 % 14.6 % 48.1 % 11.6 % 29.9 %
Unchanged 25.5 % 19.9 % 46.4 % 31.3 % 27.1 % 21.0 %
Deteriorated 2.1 % 2.1 % 2.2 % 1.5 % 2.4 % 2.4 %
Pre-treatment to six weeks post-treatment (n = 119)
Recovered 49.5 % 37.8 % 36.1 % 18.5 % 56.3 % 47.9 %
Improved 11.8 % 29.4 % 14.3 % 47.0 % 10.1 % 23.5 %
Unchanged 34.5 % 28.6 % 47.9 % 32.8 % 23.5 % 18.5 %
Deteriorated 4.2 % 4.2 % 1.7 % 1.7 % 10.1 % 10.1 %
Table 3 Descriptive statistics for patient scores on the recovery assessment scale who have been classified as recovered or not
recovered based on each DASS-21 scale using the JT and HA calculation methods
Classifications based on JT method Classifications based on HA method
Depression Anxiety Stress Depression Anxiety Stress
Classified as recovered
n 59 43 67 45 22 57
Mean 126.79 124.65 125.42 130.10 131.77 126.12
SD 14.24 17.52 13.97 13.90 17.34 14.59
Not classified as recovered
n 60 76 52 74 97 62
Mean 111.65 116.04 111.08 112.50 116.29 112.75
SD 18.76 18.04 20.02 17.42 17.29 19.04
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further support that classifying patients as recovered
according to the Jacobson-Truax method of clinical
significance calculation has construct validity when
used with a symptom measure.
Despite the differences in recovery rates between the
more lenient, popular JT method and the more conser-
vative, less commonly used HA method [15, 22], a com-
parison of effect sizes did not uncover any significant
differences between the methods. This suggests there are
no meaningful differences between how the methods
capture the construct of recovery as conceptualised by
the variables chosen in the current study. Therefore, we
echo the recommendation [1] that the JT method con-
tinue to be used since it is the most commonly used and
simplest to calculate.
Limitations
It could be argued that since the current study was cor-
relational in nature, it was not possible to determine
which method was better ‘calibrated’ towards recovery.
This is true, however the issue of calibration is an arbitrary
one, since the category of recovered has demonstrated
meaning from the perspective of both the patient and
treatment provider. Whether the ‘true’ rate of recovered
patients is indeed higher or lower than that determined by
the JT method is not relevant if the arbitrary categories
have meaning.
Although we can conclude here the JT and HA methods
appear to have similar conceptualisations of the category
of recovered, the current study does not allow for any
comment about the validity of the categories of improved,
unchanged, or deteriorated. Further research is required to
determine the relationship between belonging in each of
these categories and scores on relevant behavioural or
functional indices, as well as individual client factors. For
example, it may be that clients who are unchanged during
treatment have lower scores on readiness to change mea-
sures. If this is the case, then clinicians could employ spe-
cific techniques such as motivational interviewing [52] for
those clients who score low on a readiness to change
measure at pre-treatment, to increase their chances of
making a reliable or clinically significant change during
treatment.
Of particular concern to clinicians are those people
who deteriorate during treatment. Validity studies need
to focus on these clients, as they are not often included
Table 4 Descriptive statistics for patient scores on the quality of life enjoyment and satisfaction scale who have been classified as
“Recovered” or “Not Recovered” based on each DASS-21 scale using the JT and HA calculation methods
Classifications based on JT method Classifications based on HA method
Depression Anxiety Stress Depression Anxiety Stress
Classified as “recovered”
n 413 264 423 302 137 335
Mean 58.84 60.79 58.65 63.03 66.28 61.28
SD 15.73 16.94 16.23 14.87 16.11 15.53
Not classified as “recovered”
n 305 454 295 416 581 383
Mean 45.03 48.43 44.84 45.68 49.84 45.71
SD 19.46 18.16 19.01 17.78 17.87 18.20
Fig. 1 Proportion of patients readmitted within 28 days of discharge who are considered recovered and not recovered by the JT and HA
methods used with the DASS-21 scale scores. Error bars represent 95 % confidence intervals
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in assessments of clinical significance. One reason for
their lack of inclusion in such research may be the typic-
ally low proportion of clients who receive this classifica-
tion. Of course, having very few deteriorators in a sample
is desirable from a clinical perspective, but makes it more
difficult to explore the correlates of deterioration, as in the
current study. Since the present sample consisted of inpa-
tients that generally score high on symptom measures, the
chances of increasing symptoms enough to achieve a reli-
able deterioration are lower than in outpatient samples.
An added complexity in regards to deteriorators is that
they are not a homogenous group; the negative, reliable
change required to be classified as deteriorated can occur
anywhere along the range of the outcome measure. For
example, a deterioration based on movement from the
normal range to the mild range is qualitatively different to
a deterioration based on movement from the severe range
to the extremely severe range of a symptom measure. It
therefore follows that correlates of deterioration may be
equally as heterogeneous. Larger samples of patients are
required to meaningfully explore the correlates of this
form of patient change. Methods employed in the feed-
back literature [53–56] could then be used to predict
which patients are “at-risk” of deteriorating, allowing
clinicians to intervene during treatment. In addition to
these concerns, it is relevant to note that it is not always
possible or practical to calculate clinical significance.
That is, some scales do not (and sometimes cannot)
have relevant normative information and reliability esti-
mates and for low prevalence mental health conditions
the case for applicability needs to be made. Likewise,
while the present paper has explored to some degree
what is perceived as ‘clinically significant change,’ it is
possible that the classification may vary depending on
the perspective of the rater (i.e., client, clinician, carer,
service provider, etc).
The use of readmission to hospital within 28 days of
discharge as an index of recovery has limitations. A
small proportion (5–8 %) of patients who are classified
as recovered are readmitted to hospital within 28 days,
and not all patients who worsen (and perhaps require re-
admission) will be readmitted. Furthermore, patients
who require further treatment do not always require this
for the same reasons as a prior admission, nor do they
always seek it from the same facility. Despite this, evalu-
ating readmission is an objective, routinely used clinical
indicator of the quality of an episode of mental health
care that can provide useful information. McGlinchey et
al. [22] stated that if clinical significance classifications
are valid, then they should mean something in practical
terms, regarding whether an individual will remain re-
covered over time. In the current sample, although the
rates of readmission were lower for patients classified as
recovered than for those who were not, being assigned
this classification did not remove the possibility of re-
admission altogether. Future research should explore the
factors associated with hospital readmission subsequent
to making a clinically significant change during the initial
admission.
Since participants in the current study had diagnoses
predominantly of mood and anxiety disorders, the current
findings should generalise well to most psychiatric popula-
tions. However, for populations with mood and anxiety
disorders, scores derived from self-report measures (e.g.,
Q-LES-Q) may be influenced by patients’ current mood,
their level of insight, or recent life events [57]. This issue
is present in all self-report studies in psychiatric samples,
and relates also to the symptom measures on which
clinically significant change is measured. Furthermore,
the treatment provided to patients in the current study
was voluntary within an inpatient setting, therefore
further research may be required to explore whether
the validity of clinical significance classifications is
supported in those populations where treatment is in-
voluntary, or provided in outpatient settings. Finally,
the patients who responded in the current study were
older and had longer lengths of stay than those who
did not respond; several hypotheses could explain this
difference. However, since a focus of the study was
upon the comparison of two methods of calculating
clinical significance, the differences between respon-
dents and non-respondents were not considered rele-
vant; the more important issue was that the same
patients were included in each comparison analysis.
Conclusions
Classifying change into valid clinical significance categor-
ies following mental health treatment allows treatment
providers to evaluate treatment effectiveness, provide valid
feedback, and allows for ongoing quality improvement.
Current findings suggest that classifications of clinically
significant change made using the DASS-21 demonstrate
ecological, construct validity, since classifications of
recovered align with more positive perceptions of consumer-
based recovery, greater perceived life enjoyment and
satisfaction, and a lower chance of being readmitted to
hospital with 28 days of discharge. These results together
with validity findings in the extant literature suggest that
the commonly used Jacobson-Truax method of classifying
clinically significant change does exhibit validity, and
therefore the recommendation that clinical significance
classifications are reported in every outcome study is war-
ranted. Additionally, there was no discernible advantage to
using the HA method over the JT method, therefore the
use of the simpler, JT method, is recommended. The JT
methodology provides an easy, fast, and most importantly,
ecologically valid way to approximate the meaningfulness
of a clients’ change.
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